A multisociety Delphi consensus statement on new fatty liver disease nomenclature
University of Chicago · City University of New York · +61 more institutions
Abstract
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey…
Citation impact
- FWCI
- 159.13
- Percentile
- 100%
- References
- 33
Authors
53- MEMary E. RinellaCorresponding
University of Chicago
- JVJeffrey V. Lazarus
City University of New York, Universitat de Barcelona, The Graduate Center, CUNY, Barcelona Institute for Global Health
- VRVlad Ratziu
Sorbonne Université, Fondation pour l’innovation en Cadiométabolisme et Nutrition
- SFSven Francque
University of Antwerp, Antwerp University Hospital
- AJArun J. Sanyal
Virginia Commonwealth University
Topics & keywords
- Medicine
- Statement (logic)
- Nomenclature
- Consensus conference
- Delphi
- MEDLINE
- Fatty liver
- Disease
- Reduced inequalities
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- AAAmerican Association for the Study of Liver Diseases
- GSGilead Sciences
- APAlnylam Pharmaceuticals
- CCelgene
- MMedpace
- CBCSL Behring
- RPRegeneron Pharmaceuticals
- NNovavax
- KCKowa Company
- ZZafgen
- BPBoston Pharmaceuticals
- GGalecto
- VLVerily Life Sciences
- NBNGM Biopharmaceuticals
- CBCoherus Biosciences
- CLChildren's Liver Disease Foundation
- NUNewcastle University
- EEisai
- NNNovo Nordisk
- APAstellas Pharma
- SShionogi
- EAEuropean Association for the Study of the Liver
- SOSwedish Orphan Biovitrum
- SPSun Pharma
- IIpsen
- JCJulius Clinical
- GGenentech
- AAllergan